Myriad Genetics

Myriad Genetics MYGN Stock

$5.46   -1.444042%
Add to favorites
Market Cap
$523.74M
LOW - HIGH [24H]
$5.31 - $5.57
VOLUME [24H]
$1.25M
P/E Ratio
0
Earnings per share
-$1.35
ISIN
US62855J1043
Price   Prediction

Myriad Genetics Price Chart

Sorry, that's all we've gotfor now...

Myriad Genetics (MYGN) stock price today is 5.46 USD on Tech Market Large (-1.44% on the day). Updated .

Myriad Genetics MYGN Financial and Trading Overview

Myriad Genetics stock price 5.46 USD
Previous Close 5.54 USD
Open 5.45 USD
Bid 3.96 USD x 200
Ask 7.07 USD x 200
Day's Range 5.31 - 5.57 USD
52 Week Range 2.74 - 8.09 USD
Volume 1.25M USD
Avg. Volume 2.26M USD
Market Cap 523.74M USD
Beta (5Y Monthly) 1.607
PE Ratio (TTM) N/A
EPS (TTM) -1.35 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 5.9 USD

MYGN Valuation Measures

Enterprise Value 626.04M USD
Trailing P/E N/A
Forward P/E -8.085055
PEG Ratio (5 yr expected) 1.24
Price/Sales (ttm) 0.65173614
Price/Book (mrq) 1.9423692
Enterprise Value/Revenue 0.779
Enterprise Value/EBITDA -11.002

Trading Information

Myriad Genetics Stock Price History

Beta (5Y Monthly) 1.607
52-Week Change -24.93%
S&P500 52-Week Change 8.67%
52 Week High 8.09 USD
52 Week Low 2.74 USD
50-Day Moving Average 4.94 USD
200-Day Moving Average 4.61 USD

MYGN Share Statistics

Avg. Volume (3 month) 2.26M USD
Avg. Daily Volume (10-Days) 1.43M USD
Shares Outstanding 95.92M
Float 84.68M
Short Ratio 2.84
% Held by Insiders 3.98%
% Held by Institutions 95.40%
Shares Short 8.44M
Short % of Float 9.01%
Short % of Shares Outstanding 8.79%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 2:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -16.064%
Operating Margin (ttm) -13.32%
Gross Margin 68.32%
EBITDA Margin -7.080%

Management Effectiveness

Return on Assets (ttm) -10.010%
Return on Equity (ttm) -40.23%

Income Statement

Revenue (ttm) 803.6M USD
Revenue Per Share (ttm) 8.51 USD
Quarterly Revenue Growth (yoy) -1.50%
Gross Profit (ttm) 549.1M USD
EBITDA -56900000 USD
Net Income Avi to Common (ttm) -129100000 USD
Diluted EPS (ttm) -1.35
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 107.1M USD
Total Cash Per Share (mrq) 1.12 USD
Total Debt (mrq) 209.4M USD
Total Debt/Equity (mrq) 77.84 USD
Current Ratio (mrq) 1.976
Book Value Per Share (mrq) 2.811

Cash Flow Statement

Operating Cash Flow (ttm) -19900000 USD
Levered Free Cash Flow (ttm) 5.03M USD

Profile of Myriad Genetics

Country United States
State UT
City Salt Lake City
Address 322 North 2200 West
ZIP 84116
Phone 801 584 3600
Website https://www.myriad.com
Industry Diagnostics & Research
Sector(s) Healthcare
Full Time Employees 2700

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile, a genomic profiling test; Prequel Prenatal Screen, a prenatal screening test to screen chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess risk of passing on recessive genetic condition to offspring; SneakPeek Early Gender DNA, a non-invasive blood test that predicts the fetus's gender; FirstGene; and GeneSight Psychotropic Mental Health Medication, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company has a strategic alliance with SOPHiA GENETICS SA to advance new prostate cancer-specific genomic instability score technology for oncology approaches with AstraZeneca. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Q&A For Myriad Genetics Stock

What is a current MYGN stock price?

Myriad Genetics MYGN stock price today per share is 5.46 USD.

How to purchase Myriad Genetics stock?

You can buy MYGN shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Myriad Genetics?

The stock symbol or ticker of Myriad Genetics is MYGN.

Which industry does the Myriad Genetics company belong to?

The Myriad Genetics industry is Diagnostics & Research.

How many shares does Myriad Genetics have in circulation?

The max supply of Myriad Genetics shares is 95.92M.

What is Myriad Genetics Price to Earnings Ratio (PE Ratio)?

Myriad Genetics PE Ratio is now.

What was Myriad Genetics earnings per share over the trailing 12 months (TTM)?

Myriad Genetics EPS is -1.35 USD over the trailing 12 months.

Which sector does the Myriad Genetics company belong to?

The Myriad Genetics sector is Healthcare.

Myriad Genetics MYGN included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us Dow Jones U.S. Biotechnology In DJUSBT US 3815.19 USD —
-1.22
121.01M USD — 3805.63 USD — 3911.38 USD — — 121.01M USD —
us US Tech US 700 Small Cap Value N NQUS700SCVN US 2929.64 USD —
-1.71
— — 2925.92 USD — 3007.42 USD — — — —
us US Tech US 700 Small Cap Index NQUS700SC US 2801.87 USD —
-2.68
— — 2797.1 USD — 2892.69 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Composite Total Return XCMP US 27958.09 USD —
-5.28
— — 27828.65 USD — 29466.09 USD — — — —
us US Tech US 700 Small Cap Value I NQUS700SCV US 2545.71 USD —
-1.72
— — 2542.49 USD — 2613.31 USD — — — —
us US Tech Global Select Market Com NQGS US 11139.01 USD —
-5.31
— — 11086.73 USD — 11742.47 USD — — — —
us US Tech Biotechnology NBI US 6781.89 USD —
-1.73
— — 6767.31 USD — 6980.47 USD — — — —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
us US Tech Biotechnology Total Retu XNBI US 7414.87 USD —
-1.68
— — 7398.95 USD — 7631.86 USD — — — —
$2.05T
Total marketcap
$70.84B
Total volume
BTC 57.63%   •   ETH 9.88%
Dominance
Select currency